Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis

Observational research on sodium glucose co‐transporter‐2 inhibitors: A real breakthrough?

“…Among SGLT2‐Is, dapagliflozin accounted for 94% of the total SGLT2‐I exposure time. Over a median follow‐up of 0.9 years, the study showed that CV mortality was reduced by 47% in patients newly initiated on an SGLT2‐I compared with other glucose‐lowering medications (0.53; 0.40–0.70) 11. The CVD‐REAL Nordic was the only study examining CV mortality, which was also reduced independently of CV disease at baseline.…”

The impact of dapagliflozin on cardiovascular system in the course of type 2 diabetes mellitus

“…The study confirmed that the use of SGLT2 inhibitors significantly reduced cardiovascular mortality. Although the study included patients treated with one of three different SGLT2 inhibitors, most of the observations were from patients treated with dapagliflozin [5].…”

SGLT2-hemmere gir mindre hjertesykdom ved diabetes

“…dødsårsaksregistre og nasjonale pasientregistre (1). Alle pasienter som hentet ut en resept på glukosesenkende medisin i perioden 2012-15, ble fulgt opp ut 2015 og delt inn i to grupper: nye SGLT2-brukere og nye brukere av andre perorale antidiabetika.…”